These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38569689)

  • 1. Association between proton pump inhibitors and risk of hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt: a protocol for a systematic review and meta-analysis.
    Su Y; Chen Y; Zheng J; Yao C
    BMJ Open; 2024 Apr; 14(4):e078412. PubMed ID: 38569689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sarcopenia is a risk factor for post-transjugular intrahepatic portosystemic shunt hepatic encephalopathy and mortality: A systematic review and meta-analysis.
    Ahmed Z; Badal J; Gangwani MK; Nawaz A; Badal B; Arif SF; Farooq U; Kamal F; Javaid T; Aziz M; Lee-Smith W; Mahmood A; Merza N; Kobeissy A; Nawras A; Hassan M
    Indian J Gastroenterol; 2024 Aug; 43(4):748-759. PubMed ID: 38085501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton Pump Inhibitor Use Is Associated with an Increased Frequency of New or Worsening Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt Creation.
    Lewis DS; Lee TH; Konanur M; Ziegler C; Hall MD; Pabon-Ramos WM; Suhocki PV; Smith TP; Kim CY; Choi SS; Ronald J
    J Vasc Interv Radiol; 2019 Feb; 30(2):163-169. PubMed ID: 30638914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitor use is associated with increased rates of post-TIPS hepatic encephalopathy: Replication in an independent patient cohort.
    Dai R; Sag AA; Martin JG; Befera NT; Pabon-Ramos WM; Suhocki PV; Smith TP; Kim CY; Muir AJ; Ronald J
    Clin Imaging; 2021 Sep; 77():187-192. PubMed ID: 33940357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.
    Simonetti RG; Perricone G; Robbins HL; Battula NR; Weickert MO; Sutton R; Khan S
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD000553. PubMed ID: 33089892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic encephalopathy with proton pump inhibitor use in post tips patients: a systematic review and meta-analysis.
    Gangwani MK; Ahmed Z; Ishtiaq R; Aziz M; Rani A; Dahiya DS; Priyanka F; Arif SF; Lee-Smith W; Sohail AH; Inamdar S; Hassan M
    Minerva Gastroenterol (Torino); 2024 Sep; 70(3):353-358. PubMed ID: 37889110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
    de Wit K; Schaapman JJ; Nevens F; Verbeek J; Coenen S; Cuperus FJC; Kramer M; Tjwa ETTL; Mostafavi N; Dijkgraaf MGW; van Delden OM; Beuers UHW; Coenraad MJ; Takkenberg RB
    BMJ Open Gastroenterol; 2020 Dec; 7(1):. PubMed ID: 33372103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.
    Brand M; Prodehl L; Ede CJ
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001023. PubMed ID: 30378107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A systematic review and meta-analysis.
    Yang M; Qiu Y; Wang W
    Dig Liver Dis; 2024 Jun; 56(6):978-985. PubMed ID: 37926635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review.
    Bai M; Qi X; Yang Z; Yin Z; Nie Y; Yuan S; Wu K; Han G; Fan D
    J Gastroenterol Hepatol; 2011 Jun; 26(6):943-51. PubMed ID: 21251067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between sarcopenia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: a systematic review and meta-analysis.
    Li Y; Guo Y; Wang X; Gao L
    Abdom Radiol (NY); 2024 Feb; 49(2):575-585. PubMed ID: 37980601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expanded polytetrafluoroethylene (ePTFE)-covered stents versus bare stents for transjugular intrahepatic portosystemic shunt in people with liver cirrhosis.
    Zhu P; Dong S; Sun P; Belgaumkar AP; Sun Y; Cheng X; Zheng Q; Li T
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012358. PubMed ID: 37531575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of shunting left/right portal vein branch on post-TIPS hepatic encephalopathy: a study protocol for multicenter randomized blinded controlled trial.
    Ma J; Luo J; Zhang W; Zhou Y; Zhang Z; Yang M; Zhuang Z; Ma L; Yu J; Zhou X; Yan Z
    Trials; 2023 May; 24(1):312. PubMed ID: 37149647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refractory Hepatic Encephalopathy After Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors and Outcomes with Revision.
    Rowley MW; Choi M; Chen S; Hirsch K; Seetharam AB
    Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1765-1772. PubMed ID: 29872892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
    Nardelli S; Riggio O; Marra F; Gioia S; Saltini D; Bellafante D; Adotti V; Guasconi T; Ridola L; Rosi M; Caporali C; Fanelli F; Roccarina D; Bianchini M; Indulti F; Spagnoli A; Merli M; Vizzutti F; Schepis F
    J Hepatol; 2024 Apr; 80(4):596-602. PubMed ID: 38097113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
    Wang Z; Wu YF; Yue ZD; Zhao HW; Wang L; Fan ZH; Zhang Y; Liu FQ
    World J Gastroenterol; 2021 Feb; 27(5):416-427. PubMed ID: 33584073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with proton pump inhibitors increases the risk for development of hepatic encephalopathy after implantation of transjugular intrahepatic portosystemic shunt (TIPS).
    Sturm L; Bettinger D; Giesler M; Boettler T; Schmidt A; Buettner N; Thimme R; Schultheiss M
    United European Gastroenterol J; 2018 Nov; 6(9):1380-1390. PubMed ID: 30386611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutritional status in hepatic encephalopathy and transjugular intrahepatic portosystemic shunt - TIPS, and strategies to improve the outcomes.
    Berenguer M
    Acta Gastroenterol Belg; 2023; 86(2):318-322. PubMed ID: 37428165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-mm shunt transjugular intrahepatic portosystemic shunt in patients with severe liver atrophy and variceal bleeding.
    Yan H; Xiang Z; Zhao C; Luo S; Liu H; Li M; Huang M
    Eur Radiol; 2024 Jul; 34(7):4697-4707. PubMed ID: 38006453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early transjugular intrahepatic portosystemic shunt for acute variceal bleeding: a systematic review and meta-analysis.
    Zhou GP; Jiang YZ; Sun LY; Zhu ZJ
    Eur Radiol; 2021 Jul; 31(7):5390-5399. PubMed ID: 33409783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.